Results 41 to 50 of about 715,660 (339)

Special Issue: Monoclonal Antibodies

Antibodies, 2018
Monoclonal antibodies are utilized in clinical practice for the treatment of various diseases including cancer, autoimmunity, metabolic and infectious diseases [...]
Christian Klein
doaj   +1 more source

A Review of Therapeutic Antibodies in Breast Cancer

Journal of Pharmacy & Pharmaceutical Sciences, 2021
Since the first production of monoclonal antibodies about 35 years ago, researchers have found them useful in the treatment and diagnosis of various diseases such as cancer.
Maryam Eini, Nahid Zainodini, Hamed Montazeri, Parastoo Mirzabeigi, Parastoo Tarighi   +4 more
doaj   +1 more source

Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance [PDF]

arXiv, 2021
The latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant Omicron (B.1.1.529) has ushered panic responses around the world due to its contagious and vaccine escape mutations. The essential infectivity and antibody resistance of the SARS-CoV-2 variant are determined by its mutations on the spike (S) protein receptor-binding domain (
arxiv  

Pharmacokinetics of Monoclonal Antibodies

CPT: Pharmacometrics & Systems Pharmacology, 2017
Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens more in clinical development. This tutorial will review major drug disposition processes relevant for
Bernd Meibohm, Josiah T. Ryman
openaire   +3 more sources

On‐treatment dynamics of circulating extracellular vesicles in the first‐line setting of patients with advanced non‐small cell lung cancer: the LEXOVE prospective study

Molecular Oncology, EarlyView.
The LEXOVE prospective study evaluated plasma cell‐free extracellular vesicle (cfEV) dynamics using Bradford assay and dynamic light scattering in metastatic non‐small cell lung cancer patients undergoing first‐line treatments, correlating a ∆cfEV < 20% with improved median progression‐free survival in responders versus non‐responders.
Valerio Gristina, Viviana Bazan, Nadia Barraco, Simona Taverna, Mauro Manno, Samuele Raccosta, Anna Paola Carreca, Marco Bono, Tancredi Didier Bazan Russo, Francesco Pepe, Pasquale Pisapia, Lorena Incorvaia, Giuseppe Badalamenti, Giancarlo Troncone, Umberto Malapelle, Daniele Santini, Antonio Russo, Antonio Galvano   +17 more
wiley   +1 more source

Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

Molecular Oncology, EarlyView.
Adaptive ERK reactivation hinders FLT3 tyrosine kinase inhibitor (TKI) treatment in FLT3/ITD acute myeloid leukemia. Here, we report that FLT3 TKI treatment rapidly induces AXL expression and upregulation that is temporally associated with the adaptive ERK reactivation.
Tessa S. Seale, Li Li, J. Kyle Bruner, Melody Chou, Bao Nguyen, Jaesung Seo, Ruiqi Zhu, Mark J. Levis, Christine A. Pratilas, Donald Small   +9 more
wiley   +1 more source

MONOCLONAL ANTIBODY FOR MULTIPLE SCLEROSIS TREATMENT

Медицинский совет, 2017
Monoclonal antibodies are widely used in various fields of modern medicine, for example, in oncology, rheumatology, gastroenterology, transplantation.
E. V. Popova
doaj   +1 more source

Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system

Cardio-Oncology, 2023
Background Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients.
Abdulrazaq S. Al-Jazairi, Nahlah Bahammam, Dhai Aljuaid, Lama Almutairi, Shroog Alshahrani, Norah Albuhairan, Peter M. B. Cahusac, Ghazwa B. Korayem   +7 more
doaj   +1 more source

Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies [PDF]

arXiv, 2023
Alzheimer's disease (AD) is a prevalent, progressive, and ultimately fatal neurodegenerative disorder that is defined pathologically by the accumulation of amyloid plaques and tau neurofibrillary tangles in the brain. There remains an unmet need for therapies that can halt or slow the course of AD. To address this need, the FDA has provided a mechanism,
arxiv  

The accumulation of myeloid‐derived suppressor cells participates in abdominal infection‐induced tumor progression through the PD‐L1/PD‐1 axis

Molecular Oncology, EarlyView.
This study explores how sepsis affects GC progression by creating an immunosuppressive environment. Our findings reveal that sepsis promotes immune dysregulation, enhancing tumor growth and metastasis. Targeting the PD‐1/PD‐L1 pathway with monoclonal antibodies shows potential for restoring immune function and improving outcomes in cancer patients ...
Yiding Wang, Ting Guo, Xiaofang Xing, Xijuan Liu, Xuejun Gan, Yingai Li, Yan Liu, Fei Shan, Zhouqiao Wu, Jiafu Ji, Ziyu Li   +10 more
wiley   +1 more source